Former LTT Biopharma VP Charged For Insider Trading
This article was originally published in PharmAsia News
Executive Summary
The Japan Stock Exchange Committee charged former LTT Biopharma VP Shigenori Saito for insider trading. According to the charge, in January 2008 while Saito was the president for LTT's subsidiary Asklepios, he became aware of LTT's plan to dissolve the affiliation. In March, Saito knew that the subsidiary company could not repay its debts due to a failed investment, and from March 4 to 19, Saito sold over 11,500 company shares and pocketed ¥412 million in profit. (Click here for more - Japanese language
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.